Literature DB >> 32005653

BIRC3 mutations in chronic lymphocytic leukemia - uncommon and unfavorable.

Eugen Tausch1, Stephan Stilgenbauer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32005653      PMCID： PMC7012489          DOI： 10.3324/haematol.2019.238691

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.

Authors:  Davide Rossi; Marco Fangazio; Silvia Rasi; Tiziana Vaisitti; Sara Monti; Stefania Cresta; Sabina Chiaretti; Ilaria Del Giudice; Giulia Fabbri; Alessio Bruscaggin; Valeria Spina; Clara Deambrogi; Marilisa Marinelli; Rosella Famà; Mariangela Greco; Giulia Daniele; Francesco Forconi; Valter Gattei; Francesco Bertoni; Silvia Deaglio; Laura Pasqualucci; Anna Guarini; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2012-02-03       Impact factor: 22.113

Review 2.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

3.  ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Authors:  Matthew J J Rose-Zerilli; Jade Forster; Helen Parker; Anton Parker; Ana E Rodríguez; Tracy Chaplin; Anne Gardiner; Andrew J Steele; Andrew Collins; Bryan D Young; Anna Skowronska; Daniel Catovsky; Tatjana Stankovic; David G Oscier; Jonathan C Strefford
Journal:  Haematologica       Date:  2014-02-28       Impact factor: 9.941

4.  BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Authors:  Daniela Asslaber; Nathalie Wacht; Michael Leisch; Yuan Qi; Nicole Maeding; Clemens Hufnagl; Bettina Jansko; Nadja Zaborsky; Andreas Villunger; Tanja N Hartmann; Richard Greil; Alexander Egle
Journal:  Clin Cancer Res       Date:  2018-11-28       Impact factor: 12.531

5.  BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

Authors:  S Cheng; J Ma; A Guo; P Lu; J P Leonard; M Coleman; M Liu; J J Buggy; R R Furman; Y L Wang
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

6.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

7.  Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Authors:  J R Brown; P Hillmen; S O'Brien; J C Barrientos; N M Reddy; S E Coutre; C S Tam; S P Mulligan; U Jaeger; P M Barr; R R Furman; T J Kipps; F Cymbalista; P Thornton; F Caligaris-Cappio; J Delgado; M Montillo; S DeVos; C Moreno; J M Pagel; T Munir; J A Burger; D Chung; J Lin; L Gau; B Chang; G Cole; E Hsu; D F James; J C Byrd
Journal:  Leukemia       Date:  2017-06-08       Impact factor: 11.528

8.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Authors:  P Baliakas; A Hadzidimitriou; L-A Sutton; D Rossi; E Minga; N Villamor; M Larrayoz; J Kminkova; A Agathangelidis; Z Davis; E Tausch; E Stalika; B Kantorova; L Mansouri; L Scarfò; D Cortese; V Navrkalova; M J J Rose-Zerilli; K E Smedby; G Juliusson; A Anagnostopoulos; A M Makris; A Navarro; J Delgado; D Oscier; C Belessi; S Stilgenbauer; P Ghia; S Pospisilova; G Gaidano; E Campo; J C Strefford; K Stamatopoulos; R Rosenquist
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

9.  Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK.

Authors:  Brian J Zarnegar; Yaya Wang; Douglas J Mahoney; Paul W Dempsey; Herman H Cheung; Jeannie He; Travis Shiba; Xiaolu Yang; Wen-Chen Yeh; Tak W Mak; Robert G Korneluk; Genhong Cheng
Journal:  Nat Immunol       Date:  2008-11-09       Impact factor: 25.606

10.  Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Authors:  Fary Diop; Riccardo Moia; Chiara Favini; Elisa Spaccarotella; Lorenzo De Paoli; Alessio Bruscaggin; Valeria Spina; Lodovico Terzi-di-Bergamo; Francesca Arruga; Chiara Tarantelli; Clara Deambrogi; Silvia Rasi; Ramesh Adhinaveni; Andrea Patriarca; Simone Favini; Sruthi Sagiraju; Clive Jabangwe; Ahad A Kodipad; Denise Peroni; Francesca R Mauro; Ilaria Del Giudice; Francesco Forconi; Agostino Cortelezzi; Francesco Zaja; Riccardo Bomben; Francesca Maria Rossi; Carlo Visco; Annalisa Chiarenza; Gian Matteo Rigolin; Roberto Marasca; Marta Coscia; Omar Perbellini; Alessandra Tedeschi; Luca Laurenti; Marina Motta; David Donaldson; Phil Weir; Ken Mills; Patrick Thornton; Sarah Lawless; Francesco Bertoni; Giovanni Del Poeta; Antonio Cuneo; Antonia Follenzi; Valter Gattei; Renzo Luciano Boldorini; Mark Catherwood; Silvia Deaglio; Robin Foà; Gianluca Gaidano; Davide Rossi
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941
View more
  3 in total

Review 1.  BIRC3 and BIRC5: multi-faceted inhibitors in cancer.

Authors:  Raffaele Frazzi
Journal:  Cell Biosci       Date:  2021-01-07       Impact factor: 7.133

Review 2.  Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches.

Authors:  Vincenza Ylenia Cusenza; Alessandra Bisagni; Monia Rinaldini; Chiara Cattani; Raffaele Frazzi
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

3.  Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.

Authors:  Selcen Öztürk; Yashna Paul; Saira Afzal; Irene Gil-Farina; Anna Jauch; Peter-Martin Bruch; Verena Kalter; Bola Hanna; Lavinia Arseni; Philipp M Roessner; Manfred Schmidt; Stephan Stilgenbauer; Sascha Dietrich; Peter Lichter; Marc Zapatka; Martina Seiffert
Journal:  Leukemia       Date:  2021-08-20       Impact factor: 11.528
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.